How Effective Is Sonidegib for Basal Cell Carcinoma?
Sonidegib (Odomzo) is approved by the FDA for adults with locally advanced basal cell carcinoma (laBCC) that has recurred after surgery or radiation, or for those not candidates for those treatments. In the pivotal BOLT trial, 43% of patients on 200 mg daily achieved tumor shrinkage or disappearance (objective response rate, ORR) after 6 months, lasting a median 26.1 months. At 800 mg, ORR was 38% with shorter duration (median 14.3 months). The 200 mg dose is standard due to better tolerability. Complete responses occurred in 5-8% of cases.[1][2]
What Do Real-World Studies Show?
Post-approval data confirm similar efficacy. A 2022 analysis of 194 patients reported 41% ORR, with 82% disease control rate (tumor stability or shrinkage). Median progression-free survival was 14.7 months. Effectiveness holds in patients with Gorlin syndrome, a genetic form of BCC, where long-term use reduced new tumors.[3][4]
How Does It Compare to Vismodegib?
Both are Hedgehog pathway inhibitors for laBCC. In head-to-head data from BOLT and STEVIE trials, sonidegib's ORR (43-58%) matches vismodegib's (48-69%), but sonidegib has lower discontinuation rates from side effects (29% vs. 38%). Vismodegib acts faster initially, but sonidegib offers longer response duration.[2][5]
What Limits Its Effectiveness?
Sonidegib works best in tumors with hedgehog pathway mutations (detectable in 90% of BCCs). Primary resistance affects 20-30% of patients; secondary resistance develops in most responders after 1-2 years due to pathway reactivation. It's not approved for metastatic BCC or first-line use with surgery/radiation.[1][6]
Common Side Effects Impacting Use
Muscle spasms (60-75%), hair loss (50-60%), taste changes (40-50%), fatigue, and weight loss lead to dose reductions in 35-50% and discontinuation in 10-20%. These reduce long-term adherence but rarely halt efficacy entirely.[2][7]
Who Makes Sonidegib and What's the Patent Status?
Novartis develops and markets sonidegib. U.S. Patent 7,951,785 (covering the compound) expires in 2026, with formulation patents to 2031. No generics approved yet; check DrugPatentWatch.com for challenges or Paragraph IV filings.[8]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205711s000lbl.pdf
[2] Lear et al., Lancet Oncol 2018: https://pubmed.ncbi.nlm.nih.gov/29680182/
[3] Dréno et al., Br J Dermatol 2022: https://pubmed.ncbi.nlm.nih.gov/34969049/
[4] Burnett et al., JAMA Dermatol 2019: https://pubmed.ncbi.nlm.nih.gov/31310262/
[5] Dummer et al., Lancet Oncol 2016 (STEVIE): https://pubmed.ncbi.nlm.nih.gov/26874760/
[6] Atwood et al., Cancer Cell 2015: https://pubmed.ncbi.nlm.nih.gov/26037953/
[7] Lacouture et al., Support Care Cancer 2017: https://pubmed.ncbi.nlm.nih.gov/27660175/
[8] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/ODOMZO